| Identification | Back Directory | [Name]
2,3-DINOR PROSTAGLANDIN E1 | [CAS]
7046-40-4 | [Synonyms]
2,3-dinor PGE1
2,3-DINOR PROSTAGLANDIN E1
GTUGBRJEKVKOKQ-LRSAKWJDSA-N
2,3-dinor Prostaglandin E1
9-oxo-11α,15S-dihydroxy-2,3-dinor-prost-13E-en-1-oic acid
9-OXO-11ALPHA,15S-DIHYDROXY-2,3-DINOR-PROST-13E-EN-1-OIC ACID | [Molecular Formula]
C18H30O5 | [MDL Number]
MFCD03411990 | [MOL File]
7046-40-4.mol | [Molecular Weight]
326.43 |
| Chemical Properties | Back Directory | [Boiling point ]
508.6±50.0 °C(Predicted) | [density ]
1.164±0.06 g/cm3(Predicted) | [solubility ]
DMF: >100 mg/ml; DMSO: >50 mg/ml; Ethanol: >50 mg/ml; PBS (pH 7.2): 1.67 mg/ml | [pka]
4.75±0.10(Predicted) |
| Hazard Information | Back Directory | [Description]
Prostaglandin E1 (PGE1) is not a major naturally occurring prostaglandin, but it is widely administered clinically for several indications including peripheral occlusive vascular disease, erectile dysfunction and in neonatal cardiology.1,2 The metabolism of PGE1 is normally initiated by oxidation at C-15, resulting in 13,14-dihydro-15-keto PGE1 as the major metabolite. However, inhibition of this pathway or saturation by excess substrate could theoretically lead to enhanced production of 2,3-dinor metabolites, including 2,3-dinor PGE1. The biological activity of 2,3-dinor PGE1 has not been published. Cayman Chemical is a leading supplier of prostaglandins and their metabolites, and is currently the exclusive manufacturer of 2,3-dinor PGE1. | [Uses]
Dinorprostaglandin E1 (dinor-PGE1) is the hepatocyte metabolite of prostaglandin E1 and prostaglandin E. Prostaglandin E1 and prostaglandin E inhibit glucagon, epinephrine, isoproterenol (beta-adrenergic agonist), or epinephrine-stimulated glycogenolysis when co-treated with Isoproterenol (HY-B0468)[1]. | [Definition]
ChEBI: 2,3-Dinor-PGE1 is a prostanoid. | [References]
1. Virag, R., Shoukry, K., Floresco, J., et al. Intracavernous self-injection of vasoactive drugs in the treatment of impotence: 8-Year experience with 615 cases J. Urol. 145(2),287-293(1991).
2. Hoshi, K. Approved indications of lipo-PGE1 in Japan Adv. Drug Deliv. Rev. 20(2-3),171-176(1996). |
|
|